Our albumin-fusion technology allows us to create long-acting forms of protein drugs by fusing the gene that expresses human albumin to the gene that expresses a therapeutically active protein. We and our partners are actively pursuing the development of albumin-fusion drugs based on therapeutic proteins already on the market, as well as albumin-fusion versions of therapeutic proteins that we are developing ourselves. For example, ZALBIN™ (albinterferon alfa-2b) results from the genetic fusion of human albumin and human interferon-alpha, and Syncria results from the genetic fusion of human albumin and glucagon-like peptide-1 (GLP-1).

Based on preclinical and clinical results to date, we believe that albumin-fusion proteins may provide long-acting treatment options that have efficacy and safety similar to or better than that of existing protein drugs, with the potential additional benefit of considerably more convenient dosage schedules. Albumin-fusion technology also provides for efficient manufacture and purification of the product in our existing facilities.

Click here for a comprehensive recent scientific article on albumin-fusion technology.